Annual report
3937.TEDINET S100YHAT
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 156
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥6.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥5.9bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.7bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.3bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥1.3bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥1.3bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥936m | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.3bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.3bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥892m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥858m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥526m | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥574m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥832m | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥893m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥858m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥8.0bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥7.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥6.9bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.8bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.6bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.0bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥2.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.0bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.7bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥4.1bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥3.8bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.2bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.2bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.6bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.3bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥984m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥931m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥727m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥821m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥874m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥58m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥19m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥273m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥111m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥203m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥627m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥126m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥155m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥447m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥152m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥73.56 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥71.13 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.73 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.68 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.38 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥71.11 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥44.15 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥47.57 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥68.49 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥496.46 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥456.77 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥395.82 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥348.19 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥322.44 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 75.5% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 15.4% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.0% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 14.5% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 24.6% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 992 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 977 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,088 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 1,065 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 947 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥3.1bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥3.8bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥2.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.8bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.6bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥647m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥737m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥872m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥359m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥226m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥233m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥870m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥890m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥341m | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥177m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥384m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥4.0bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥4.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥3.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.5bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.4bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥362m | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥683m | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.7bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.4bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.3bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥2.1bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.9bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥73.4 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥88.16 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.45 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥88.13 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥28.62 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥14.66 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.57 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥40 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥13 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥11 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥9 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥302.95 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥272.14 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥188.33 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥164.58 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥173.83 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 90.9% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.5% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.5% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.5% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.0% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 25.5% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 38.5% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.1% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 20.2% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 12,249,920 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,249,920 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,991,120 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,873,840 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,834,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 55 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 50 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 54 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 57 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 58 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 74
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥4m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥9m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥76m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥76m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥2.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥353m |
| Medical Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥57m |
| Medical Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥11m |
| Medical Businessreportable segment | employees | at 2026-03-31 | 53 pure |
| Medical Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.0bn |
| Medical Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥1.9bn |
| Medical Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥4m |
| Medical Businessreportable segment | segment assets | at 2026-03-31 | ¥3.1bn |
| Medical Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.2bn |
| Technology Consultingreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥48m |
| Technology Consultingreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥158m |
| Technology Consultingreportable segment | employees | at 2026-03-31 | 928 pure |
| Technology Consultingreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥4.1bn |
| Technology Consultingreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥4.0bn |
| Technology Consultingreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥72m |
| Technology Consultingreportable segment | segment assets | at 2026-03-31 | ¥2.7bn |
| Technology Consultingreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥431m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥105m |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥170m |
| —segment total | employees | at 2026-03-31 | 981 pure |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥6.1bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥6.0bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥76m |
| —segment total | segment assets | at 2026-03-31 | ¥5.8bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥105m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥170m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥6.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥6.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥76m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥1.7bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥10m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥11m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥43m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥43m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥375m |
| Medical Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥9m |
| Medical Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥9m |
| Medical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Medical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Medical Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥13m |
| Medical Businessreportable segment | segment assets | at 2025-03-31 | ¥2.8bn |
| Medical Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Technology Consultingreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥290m |
| Technology Consultingreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥177m |
| Technology Consultingreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥4.6bn |
| Technology Consultingreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.6bn |
| Technology Consultingreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥31m |
| Technology Consultingreportable segment | segment assets | at 2025-03-31 | ¥3.0bn |
| Technology Consultingreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥562m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥300m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥186m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥6.4bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥6.3bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥43m |
| —segment total | segment assets | at 2025-03-31 | ¥5.8bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥300m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥186m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥43m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Medical Businessreportable segment | employees | at 2026-03-31 | 1 pure |
| Technology Consultingreportable segment | employees | at 2026-03-31 | 43 pure |
| —segment total | employees | at 2026-03-31 | 44 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,501
| Item | Context | Value | Unit |
|---|---|---|---|
| Loss gain on investments in partnership ope cf | Prior1YearDuration | -7857000 | JPY |
| Loss gain on investments in partnership ope cf | CurrentYearDuration | 15480000 | JPY |
| Decrease increase in accounts receivable trade and contract assets ope cf | Prior1YearDuration | -122683000 | JPY |
| Decrease increase in accounts receivable trade and contract assets ope cf | CurrentYearDuration | 115564000 | JPY |
| Decrease increase in inventories ope cf | Prior1YearDuration | 24000 | JPY |
| Decrease increase in inventories ope cf | CurrentYearDuration | 407000 | JPY |
| Decrease increase in accounts receivable other ope cf | Prior1YearDuration | 9454000 | JPY |
| Decrease increase in accounts receivable other ope cf | CurrentYearDuration | 11697000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YearDuration | 8840000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYearDuration | -46343000 | JPY |
| Increase decrease in contract liabilities ope cf | Prior1YearDuration | 20005000 | JPY |
| Increase decrease in contract liabilities ope cf | CurrentYearDuration | 13761000 | JPY |
| Decrease increase in other current assets ope cf | Prior1YearDuration | -11543000 | JPY |
| Decrease increase in other current assets ope cf | CurrentYearDuration | -19967000 | JPY |
| Decrease increase in other noncurrent assets ope cf | Prior1YearDuration | -6845000 | JPY |
| Decrease increase in other noncurrent assets ope cf | CurrentYearDuration | -430000 | JPY |
| Increase decrease in other current liabilities ope cf | Prior1YearDuration | -8896000 | JPY |
| Increase decrease in other current liabilities ope cf | CurrentYearDuration | -28224000 | JPY |
| Other net ope cf | Prior1YearDuration | 4508000 | JPY |
| Other net ope cf | CurrentYearDuration | 3816000 | JPY |
| Subtotal ope cf | Prior1YearDuration | 1410528000 | JPY |
| Subtotal ope cf | CurrentYearDuration | 1512597000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YearDuration | 12732000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYearDuration | 10694000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YearDuration | -17522000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYearDuration | -28235000 | JPY |
| Income taxes paid ope cf | Prior1YearDuration | -476509000 | JPY |
| Income taxes paid ope cf | CurrentYearDuration | -511830000 | JPY |
| Income taxes refund ope cf | Prior1YearDuration | 1602000 | JPY |
| Income taxes refund ope cf | CurrentYearDuration | 842000 | JPY |
| Net cash provided by used in operating activities | Prior1YearDuration | 930831000 | JPY |
| Net cash provided by used in operating activities | CurrentYearDuration | 984068000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YearDuration | － | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYearDuration | 59530000 | JPY |
| Purchase of investment securities inv cf | Prior1YearDuration | -32943000 | JPY |
| Purchase of investment securities inv cf | CurrentYearDuration | － | JPY |
| Proceeds from redemption of investment securities inv cf | Prior1YearDuration | 100587000 | JPY |
| Proceeds from redemption of investment securities inv cf | CurrentYearDuration | － | JPY |
| Purchase of property plant and equipment inv cf | Prior1YearDuration | -27307000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYearDuration | -26467000 | JPY |
| Purchase of intangible assets inv cf | Prior1YearDuration | -21365000 | JPY |
| Purchase of intangible assets inv cf | CurrentYearDuration | -78347000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YearDuration | － | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYearDuration | 1375000 | JPY |
| Purchase of investments in subsidiaries resulting in change of scope of consolidation inv cf | Prior1YearDuration | － | JPY |
| Purchase of investments in subsidiaries resulting in change of scope of consolidation inv cf | CurrentYearDuration | -8453000 | JPY |
| Payments for lease and guarantee deposits inv cf | Prior1YearDuration | － | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYearDuration | -7313000 | JPY |
| Other net inv cf | Prior1YearDuration | -170000 | JPY |
| Other net inv cf | CurrentYearDuration | 1806000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |